Condition: Cutaneous Melanoma · Mucosal Melanoma · Cutaneous Squamous Cell Carcinoma (CSCC) · Sponsor: Kupando GmbH
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
This description comes directly from the study's public registry record.
Clinical Operations · +49 30 52 00 58 60 20 · clinicaltrials@kupando.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Würzburg | Würzburg, Bavaria, Germany | Recruiting |
| Fachklinik Hornheide | Münster, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600476